News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
827,272 Results
Type
Article (85366)
Company Profile (695)
Press Release (741211)
Section
Business (231881)
Career Advice (4102)
Deals (39636)
Drug Delivery (113)
Drug Development (90513)
Employer Resources (194)
FDA (17901)
Job Trends (17265)
News (394873)
Policy (39578)
Tag
Academia (2972)
Alliances (56338)
Alzheimer's disease (1307)
Approvals (17832)
Artificial intelligence (121)
Bankruptcy (394)
Best Places to Work (12389)
Biosimilars (84)
Biotechnology (478)
Breast cancer (97)
Cancer (906)
Career advice (3509)
Cell therapy (229)
Clinical research (71039)
Collaboration (320)
Compensation (147)
COVID-19 (2777)
Data (828)
Diabetes (106)
Diagnostics (6577)
Earnings (93930)
Employer resources (166)
Events (125859)
Executive appointments (221)
FDA (18260)
Funding (264)
Gene therapy (164)
GLP-1 (625)
Government (5016)
Healthcare (20622)
Infectious disease (2839)
Inflammatory bowel disease (114)
Interviews (807)
IPO (17520)
Job creations (5177)
Job search strategy (2853)
Layoffs (481)
Legal (10011)
Lung cancer (147)
Manufacturing (161)
Medical device (14243)
Medtech (14248)
Mergers & acquisitions (22014)
Metabolic disorders (350)
Neuroscience (1542)
NextGen Class of 2024 (7643)
Non-profit (5046)
Northern California (1170)
Obesity (200)
Opinion (241)
Patents (93)
People (63912)
Pharmaceutical (136)
Phase I (21874)
Phase II (30855)
Phase III (23271)
Pipeline (303)
Podcasts (87)
Postmarket research (3533)
Preclinical (9891)
Radiopharmaceuticals (241)
Rare diseases (180)
Real estate (7366)
Regulatory (25749)
Research institute (2637)
Resumes & cover letters (648)
Southern California (1053)
Startups (4271)
United States (11472)
Vaccines (613)
Weight loss (171)
Date
Today (205)
Last 7 days (921)
Last 30 days (2761)
Last 365 days (35523)
2024 (30940)
2023 (42566)
2022 (53928)
2021 (58726)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1262)
Arizona (212)
Asia (49139)
Australia (8661)
California (2708)
Canada (1020)
China (207)
Colorado (91)
Connecticut (107)
Europe (112480)
Florida (318)
Georgia (81)
Illinois (325)
Indiana (175)
Kansas (103)
Maryland (549)
Massachusetts (2325)
Michigan (136)
Minnesota (236)
New Jersey (807)
New York (792)
North Carolina (764)
Northern California (1170)
Ohio (115)
Pennsylvania (675)
South America (1646)
Southern California (1053)
Texas (340)
Washington State (333)
827,272 Results for "121 bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
October 29, 2024
·
6 min read
BioCapital
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).
June 18, 2024
·
9 min read
Drug Development
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC
Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prostate cancer (mCRPC).
June 5, 2024
·
1 min read
Layoffs
Bluebird Bio to Lay Off 25% of Workforce
About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D.
September 24, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Mercury Bio Appoints Biotech Innovator Alex Koglin, Ph.D. to Board of Directors
With the addition of NTx’s co-founder and former President to the board Mercury Bio significantly enhances its strategic reach in the biotech sector
October 1, 2024
·
2 min read
Amgen-Backed Seismic Secures $121M in Series B Funding
Mass.-based Seismic Therapeutic secured a new investor in Bessemer Venture Partners and $121 million in its Series B round as it looks to push its two lead candidates into the clinic.
December 4, 2023
·
2 min read
·
Tyler Patchen
Pharm Country
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
Intelligent Bio Solutions Inc. today announced that its management team will participate in the Sidoti Small-Cap Conference being held virtually June 12-13, 2024.
June 6, 2024
·
1 min read
Drug Development
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
REGENXBIO Inc. (Nasdaq: RGNX) today announced topline results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II) demonstrating that the pivotal phase of the trial met its primary endpoint with statistical significance.
February 7, 2024
·
10 min read
Layoffs
IN8bio to Lay Off About 49% of Employees
Facing financial challenges, IN8bio is looking to preserve cash resources through a pipeline prioritization and layoffs at its New York City and Birmingham, Alabama, sites.
September 5, 2024
·
1 min read
·
Angela Gabriel
Genetown
Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform
Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that it has closed a $121 million Series B financing.
December 4, 2023
·
5 min read
1 of 82,728
Next
